Relationship between carbamazepine concentrations in serum and saliva of Thai epileptic patients

Piyaporn Kaewdoung, Chartchai Puripokai, Chartchai Puripokai, Mayuree H Tantisira, Somsong Laanwprasert

Abstract


This study aims to examine and verify the correlation between serum and saliva carbamaze
pine concentrations in Thai epileptic patients. The subjects were patients aged 15-60 years old who were under treatment
with carbamazepine. Carbamazepine concentrations in the blood and saliva samples were measured by a fluorescence polarization immunoassay.
Blood and saliva samples of 12 patients receiving carbamazepine monotherapy were collected before and at 1, 3, 5 and 8 h after carbamazepine administration to construct
a regression equation of the relationship between serum and saliva carbamazepine concentrations. Based on the
results obtained, a significant linear correlation between the serum (y) and saliva (x) carbamazepine concentrations (r = 0.929, p<0.001) with a regression equation of y = 2.402x + 2.397 was demonstrated and being further verified by blood and saliva samples of 30 patients collected before and at 3 h after carbamazepine administration. By using
the constructed regression equation, saliva carbamazepine concentrations of these 30 patients were used to estimate
their respective calculated serum carbamazepine concentrations. As expected, no significant difference between the
calculated and the measured carbamazepine concentrations in serum collected before carbamazepine administration in these patients.
The results of the present study support the use of saliva as an alternative to serum for monitoring carbamazepine therapy.


Full Text:

21-27:PDF

References


J.O. McNamara. Pharmacotherapy of the epilepsies. In: L.L. Brunton, B.A.

Chabner, and B.C. Knollmann (eds.), Goodman & Gilman’s The Pharmacological

Basis of Therapeutics, McGraw-Hill, New York, 2011, pp. 583-607.

C. Van Valkenburg, J.C. Kluznik, and R. Merrill. New uses of anticonvulsant

drugs in psychosis. Drugs. 44: 326-335 (1992).

R.J. Baumann. Salivary monitoring of antiepileptic drugs. J. Pharm. Pract. 20:

-157 (2007).

H.G.M. Westenberg, R.A.D. Zeeuw, E.V.D. Kleijn, and T.T.Oei. Relationship

between carbamazepine concentrations in plasma and saliva in man as determined by

liquid chromatography. Clinica Chimica Acta. 79: 155-161 (1977).

J.J. MacKichan, P.K. Duffner, and M.E. Cohen. Salivary concentrations and

plasma protein binding of carbamazepine and carbamazepine 10, 11-epoxide in

epileptic patients. Br. J. Clin. Pharmacol. 12: 31-37 (1981).

T.A. Moreland, D.A. Priestman, and G.W. Rylance. Saliva carbamazepine levels

in children before and during multiple dosing. Br. J. Clin. Pharmacol. 13: 647-651

(1982).

O. Eeg-Olofsson, H.L. Nilsson, B.Tonnby, J. Arvidsson, P.A. Grahn, H. Gylje, C.

Larsson, and L. Noren. Diurnal variation of carbamazepine and carbamazepine-10,

-epoxide in plasma and saliva in children with epilepsy: A comparison between

conventional and slow-release formulations. J. Child. Neurol. 5(2): 159-165 (1990).

K.Y. Chee, D. Lee, D. Byron, D. Naidoo, and A. Bye. A simple collection method

for saliva in children: potential for home monitoring of carbamazepine therapy. Br. J.

Clin. Pharmacol. 35(3); 311-313 (1993).

R. Gorodischer, P. Burtin, Z. Verjee, P. Hwang, and G. Koren. Is saliva suitable

for therapeutic monitoring of anticonvulsants in children: An evaluation in the routine

clinical setting. Ther. Drug Monit. 19(6): 637-642 (1997).

J.J. McAuliffe, A.L. Sherwin, I. Leppik, S.A. Fayle, and C.E. Pippenger. Salivary

levels of anticonvulsants: A practical approach to drug monitoring. Neurology. 27(5):

-413 (1977).

G.W. Rylance, and T.A. Moreland. Saliva carbamazepine and phenytoin level

monitoring. Arch. Dis. Child. 56: 637-652 (1981).

R.F. Goldsmith, and R.A. Ouvrier. Salivary anticonvulsant levels in children: a

comparison of methods. Ther. Drug Monit. 3: 151-157 (1981).

C. Knott, and F. Reynolds. The place of saliva in antiepileptic drug monitoring.

Ther. Drug Monit. 6: 35-41 (1984).

M.V. Miles, M.B. Tennison, R.S. Greenwood, S.E. Benoit, M.D. Thorn, J.A.

Messenheimer, and A.L. Ehle. Evaluation of the Ames seralyzer for the determination

of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Ther. Drug

Monit. 12: 501-510 (1990).

M.V. Miles, M.B. Tennison, and R.S. Greenwood. Intraindividual variability of

carbamazepine, Phenobarbital, and phenytoin concentrations in saliva. Ther. Drug

Monit. 13: 166-171 (1991).

E. Rosenthal, E. Hoffer, H. Ben-Aryeh, S. Badarni, A. Benderly, and Y. Hemli.

Use of saliva in home monitoring of carbamazepine levels. Epilepsia. 36(1): 72-74

(1995).

M.A.Z. Abi, D. Deleu, and C. Batchelor. Salivary free concentrations of anti-

epileptic drugs: an evaluation in a routine clinical setting. Acta Neurol. Belg. 103: 19-

(2003).

H. Bartels, H.D. Oldigs, and E. Gunther. Use of saliva in monitoring

carbamazepine medication in epileptic children. Europ. J. Pediat. 126: 37-44 (1977).

O. Kristensen, and H.F. Larsen. Value of saliva samples in monitoring

carbamazepine concentrations in epileptic patients. Acta Neurol. Scandinav. 61: 344-

(1980).

J.W. Paxton, and R.A. Donald. Concentrations and kinetics of carbamazepine in

whole saliva, parotid saliva, serum ultrafiltrate, and serum. Clin. Pharmacol. Ther.

(5): 695-702 (1980).

G.M.Van Hoeck. Comparative study of the levels of anticonvulsants and their

free fractions in venous blood, saliva and capillary blood in man. J. Pharmacol. 15(1):

-35 (1984).

P.N. Patsalos, and D.J. Berry. Therapeutic drug monitoring of antiepileptic drugs

by saliva. Ther. Drug Monit. 35(1): 4-29 (2013).

H. Liu, and M.R. Delgado. Therapeutic drug concentration monitoring using

saliva samples: Focus on anticonvulsants. Clin. Pharmacokinet. 36(6): 453-470

(1999).

The United States Department of Health and Human Services, Food and Drug

Administration, Center for Veterinary Medicine. Guidance for industry: Bioanalytical

Method Validation. [online]. 2001. Available from

http://www.fda.gov/CDER/GUIDANCE/4352fnl.htm [2011, May 21].

M.J. Eadie. Therapeutic drug monitoring-antiepileptic drugs. Br. J. Clin.

Pharmacol. 46: 185-193 (1998).

R. Haeckel. Factors influencing the saliva/plasma ratio of drugs. Ann. NY.Acad.

Sci. 694: 128-142 (1993).


Refbacks

  • There are currently no refbacks.